Payment overview · 2025
General Payments
$1,321.93
70 reported records · 19 companies
Healthcare provider profile · identity verified
Bryan T Arnette, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WEBER CITY, VA · NPI 1023047768
Verified facts
What the public records show
CMS Open Payments records show Bryan T Arnette, MD received $1,321.93 in general payments during 2025 across 70 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Nexletol, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $256.12 | 19.4% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $181.51 | 13.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $150.53 | 11.4% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $140.54 | 10.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.66 | 6.9% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $65.61 | 5.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.18 | 4.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $57.39 | 4.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.34 | 3.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $37.88 | 2.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.28 | 2.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $36.20 | 2.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.55 | 2.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.80 | 2.6% | 2 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $23.98 | 1.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.08 | 1.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.56 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.59 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.13 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,321.93 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $184.83 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $181.51 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $159.04 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $140.54 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.13 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $106.51 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $106.51 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $95.38 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $65.61 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.18 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $57.39 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.02 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $37.28 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.55 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.55 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 229 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 98 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
229 | 36 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
98 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
229 | 36 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 602 | 156 |
| Oxycodone Hcl | Oxycodone Hcl | 538 | 62 |
| Lisinopril | Lisinopril | 528 | 140 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 523 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 521 | 131 |
| Alprazolam | Alprazolam | 520 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 469 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 421 | 105 |
| Omeprazole | Omeprazole | 414 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 399 | 109 |
| Gabapentin | Gabapentin | 394 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 366 | 85 |
| Furosemide | Furosemide | 349 | 102 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 328 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 299 | 78 |
| Potassium Chloride | Potassium Chloride | 290 | 84 |
| Baclofen | Baclofen | 277 | 77 |
| Metformin Hcl Er | Metformin Hcl | 257 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 67 |
| Montelukast Sodium | Montelukast Sodium | 253 | 60 |
| Valsartan | Valsartan | 247 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 235 | 64 |
| Eliquis | Apixaban | 229 | 36 |
| Trazodone Hcl | Trazodone Hcl | 213 | 45 |
| Allopurinol | Allopurinol | 208 | 49 |
| Losartan Potassium | Losartan Potassium | 205 | 51 |
| Famotidine | Famotidine | 196 | 59 |
| Metformin Hcl | Metformin Hcl | 189 | 52 |
| Celecoxib | Celecoxib | 188 | 44 |
| Simvastatin | Simvastatin | 180 | 47 |
| Ezetimibe | Ezetimibe | 178 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 41 |
| Ondansetron Odt | Ondansetron | 143 | 47 |
| Lorazepam | Lorazepam | 137 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 132 | 38 |
| Atenolol | Atenolol | 129 | 36 |
| Carvedilol | Carvedilol | 129 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 115 | 24 |
| Tramadol Hcl | Tramadol Hcl | 115 | 26 |
| Meloxicam | Meloxicam | 114 | 30 |
| Prednisone | Prednisone | 113 | 52 |
| Diazepam | Diazepam | 112 | 16 |
| Chlorthalidone | Chlorthalidone | 111 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 110 | 100 |
| Buspirone Hcl | Buspirone Hcl | 107 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 24 |
| Mounjaro | Tirzepatide | 98 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 95 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 91 | 21 |
| Benazepril Hcl | Benazepril Hcl | 90 | 22 |
| Nifedipine Er | Nifedipine | 88 | 19 |
| Finasteride | Finasteride | 86 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 18 |
| Clonazepam | Clonazepam | 83 | 13 |
| Fluconazole | Fluconazole | 83 | 40 |
| Mirtazapine | Mirtazapine | 83 | 20 |
| Cefdinir | Cefdinir | 82 | 71 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 81 | 64 |
| Warfarin Sodium | Warfarin Sodium | 80 | 15 |
| Pregabalin | Pregabalin | 79 | 17 |
| Jardiance | Empagliflozin | 78 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 19 |
| Sucralfate | Sucralfate | 75 | 25 |
| Glipizide Er | Glipizide | 72 | 18 |
| Metolazone | Metolazone | 72 | 15 |
| Sertraline Hcl | Sertraline Hcl | 72 | 17 |
| Morphine Sulfate Er | Morphine Sulfate | 70 | suppressed |
| Lovastatin | Lovastatin | 69 | 18 |
| Spironolactone | Spironolactone | 66 | 21 |
| Donepezil Hcl | Donepezil Hcl | 65 | 20 |
| Fenofibrate | Fenofibrate | 65 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 16 |
| Bupropion Xl | Bupropion Hcl | 61 | 12 |
| Novolog Flexpen | Insulin Aspart | 61 | 18 |
| Methocarbamol | Methocarbamol | 59 | 13 |
| Synthroid | Levothyroxine Sodium | 58 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 14 |
| Prazosin Hcl | Prazosin Hcl | 54 | 11 |
| Promethazine Hcl | Promethazine Hcl | 54 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 38 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 36 |
| Mupirocin | Mupirocin | 45 | 36 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Glipizide | Glipizide | 41 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 40 | suppressed |
| Ozempic | Semaglutide | 40 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 39 | suppressed |
| Irbesartan | Irbesartan | 38 | 11 |
| Meclizine Hcl | Meclizine Hcl | 38 | 13 |
| Nitroglycerin | Nitroglycerin | 38 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 29 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 34 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Carisoprodol | Carisoprodol | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 28 | suppressed |
| Rexulti | Brexpiprazole | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Klor-Con M10 | Potassium Chloride | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Nucynta Er | Tapentadol Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,321.93 · 70 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, INTELLIS ADAPTIVESTIM, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, QULIPTA, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, Veozah, XIFAXAN, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error